These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24718961)

  • 1. Hyperuricaemia and gout: time for a new staging system?
    Dalbeth N; Stamp L
    Ann Rheum Dis; 2014 Sep; 73(9):1598-600. PubMed ID: 24718961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MSU crystal deposition contributes to inflammation and immune responses in gout remission.
    Gu H; Yu H; Qin L; Yu H; Song Y; Chen G; Zhao D; Wang S; Xue W; Wang L; Ai Z; Xu B; Peng A
    Cell Rep; 2023 Oct; 42(10):113139. PubMed ID: 37756161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous resolution of acute gout: mechanisms and therapeutic targets.
    Shi M; Luo J; Ding L; Duan L
    RMD Open; 2023 Sep; 9(3):. PubMed ID: 37734872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between gout flares and monosodium urate burden assessed using musculoskeletal ultrasound in patients with gout.
    Yang S; Lin X; Gao Y; Liang N; Han Y; Sun H; Qu S; Chen H
    Ther Adv Musculoskelet Dis; 2024; 16():1759720X241240837. PubMed ID: 38559313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperuricaemia with deposition: latest evidence and therapeutic approach.
    Perez-Ruiz F; Marimon E; Chinchilla SP
    Ther Adv Musculoskelet Dis; 2015 Dec; 7(6):225-33. PubMed ID: 26622324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperuricemia remodels the serum proteome toward a higher inflammatory state.
    Cabău G; Gaal O; Badii M; Nica V; Mirea AM; Hotea I; ; Pamfil C; Popp RA; Netea MG; Rednic S; Crișan TO; Joosten LAB
    iScience; 2023 Oct; 26(10):107909. PubMed ID: 37810213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum soluble E-cadherin is a new potential marker for assessing the severity of gout.
    Zhao Q; Xiong Y; Man X; Liu Y; Huang Y; Chen W; Wang B
    Clin Exp Rheumatol; 2023 May; 41(5):1170-1178. PubMed ID: 36305356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Inquiry into the Proximate Cause of Gout and Its Rational Treatment.
    White A
    Med Exam (Phila); 1852 Sep; 8(93):595-603. PubMed ID: 38121226
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature.
    van Durme C; van Echteld IA; Falzon L; Aletaha D; van der Heijde DM; Landewé RB
    J Rheumatol Suppl; 2014 Sep; 92():9-14. PubMed ID: 25180123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis, treatment, and prevention of gout.
    Hainer BL; Matheson E; Wilkes RT
    Am Fam Physician; 2014 Dec; 90(12):831-6. PubMed ID: 25591183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular physiology of uric acid homeostasis.
    Mandal AK; Mount DB
    Annu Rev Physiol; 2015; 77():323-45. PubMed ID: 25422986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary supplements for chronic gout.
    Andrés M; Sivera F; Falzon L; Buchbinder R; Carmona L
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010156. PubMed ID: 25287939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review.
    Vinik O; Wechalekar MD; Falzon L; Buchbinder R; van der Heijde DM; Bombardier C
    J Rheumatol Suppl; 2014 Sep; 92():70-4. PubMed ID: 25180131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street.
    Karis E; Crittenden DB; Pillinger MH
    South Med J; 2014 Apr; 107(4):235-41. PubMed ID: 24937517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2016 updated EULAR evidence-based recommendations for the management of gout.
    Richette P; Doherty M; Pascual E; Barskova V; Becce F; Castañeda-Sanabria J; Coyfish M; Guillo S; Jansen TL; Janssens H; Lioté F; Mallen C; Nuki G; Perez-Ruiz F; Pimentao J; Punzi L; Pywell T; So A; Tausche AK; Uhlig T; Zavada J; Zhang W; Tubach F; Bardin T
    Ann Rheum Dis; 2017 Jan; 76(1):29-42. PubMed ID: 27457514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.
    Dalbeth N; Phipps-Green A; Frampton C; Neogi T; Taylor WJ; Merriman TR
    Ann Rheum Dis; 2018 Jul; 77(7):1048-1052. PubMed ID: 29463518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
    Neogi T; Jansen TL; Dalbeth N; Fransen J; Schumacher HR; Berendsen D; Brown M; Choi H; Edwards NL; Janssens HJ; Lioté F; Naden RP; Nuki G; Ogdie A; Perez-Ruiz F; Saag K; Singh JA; Sundy JS; Tausche AK; Vaquez-Mellado J; Yarows SA; Taylor WJ
    Ann Rheum Dis; 2015 Oct; 74(10):1789-98. PubMed ID: 26359487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gout.
    Dalbeth N; Merriman TR; Stamp LK
    Lancet; 2016 Oct; 388(10055):2039-2052. PubMed ID: 27112094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global epidemiology of gout: prevalence, incidence and risk factors.
    Kuo CF; Grainge MJ; Zhang W; Doherty M
    Nat Rev Rheumatol; 2015 Nov; 11(11):649-62. PubMed ID: 26150127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.